Leap Therapeutics Special Meeting Summary (12/15/2025)

Leap Therapeutics is seeking stockholder approval on five proposals following a $58.89 million private placement (closed Oct 2025) led by Winklevoss Capital. Proceeds fund clinical programs (FL-501, sirexatamab) and a new digital asset treasury strategy. Winklevoss Capital also gains nomination rights for two directors, including one Board Chair.

Critical Proposals Requiring Vote:

• Authorized Share Increase (Proposal 1): Double authorized shares from 250M to 500M for future flexibility.
• **Reverse Stock Split (Prop